Biopharmaceutical Development
Biopharmaceutical Development - Related Videos
01:28
Biopharmaceutics and Pharmacokinetics: Overview
0 Views •
2024
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:23
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
0 Views •
2024
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy. Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:22
Biopharmaceutical Factors Influencing Drug Product Design: Overview
0 Views •
2025
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
11:09
An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry
0 Views •
Cited by 9 •
2018
Here, we describe a chromatographic assay coupled with the ion mobility separation of peptide precursors followed by the high-resolution (~30,000) MS-detection of peptide fragments for the quantification of spiked peptide standards in a monoclonal antibody digest.
10:16
Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes
0 Views •
Cited by 3 •
2019
Here, we present a protocol to produce an oral vaccine candidate against Type 1 diabetes in an edible plant.
FAQs
Genetic engineering directs a host cell to express a selected therapeutic molecule. This makes the host part of the production strategy and links the molecule’s intended structure to the cellular system used to generate it. In practice, researchers must evaluate whether the resulting product can proceed through purification, structural characterization, formulation, and quality testing.
Purification separates the therapeutic molecule from the broader production mixture, while structural characterization examines the molecule’s properties after recovery. These steps answer different questions: one supports product consistency, and the other helps determine whether the molecule has the relevant structure. Together, they connect manufacturing decisions with biochemical requirements for activity, stability, and evaluation.
These properties help determine whether a biologic remains suitable for development and use. Stability concerns the product’s ability to retain its relevant characteristics, activity reflects its intended biological function, and interactions describe how it behaves with other molecular components. Evaluating them supports optimization of efficacy, safety, formulation, and consistent quality.
A development pathway can begin with designing a therapeutic molecule and engineering host cells to produce it. The resulting material then undergoes purification, structural characterization, formulation, and quality testing. These activities continue into clinical development, where the product is evaluated while researchers refine its efficacy, safety, manufacturability, and regulatory performance.
The field supports several biologic product categories, including vaccines, enzyme therapies, antibodies, proteins, and nucleic-acid-based medicines. Their inclusion reflects the breadth of molecules that can be designed, produced, and evaluated through biological systems. The same development framework helps connect each product’s molecular properties with requirements for quality and therapeutic performance.
Biochemistry provides the basis for relating molecular structure to stability, activity, and interactions. Those relationships guide choices throughout development, from expression in host cells through purification, formulation, and quality testing. This perspective helps researchers assess whether a candidate has properties compatible with efficacy, safety, reproducible manufacture, and progression toward clinical development.
A biologic must perform its intended therapeutic role while also being suitable for consistent production and evaluation. Focusing only on efficacy would not address purification, formulation, quality testing, or regulatory performance. Considering manufacturability alongside safety and activity allows researchers to identify products whose molecular and production characteristics can support continued development.
Early molecular design and production choices establish information that is later examined through structural characterization, formulation, and quality testing. These data help researchers optimize efficacy, safety, and manufacturability before and during clinical development. The resulting continuity links biochemical understanding of the product with the consistency and regulatory performance expected of a medicine.